Article
EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
American journal of clinical pathology - 1 Apr 2009
Sartori Giuliana, Cavazza Alberto, Sgambato Alessandro, Marchioni Alessandro, Barbieri Fausto, Longo Lucia, Bavieri Mario, Murer Bruno, Meschiari Emmanuela, Tamberi Stefano, Cadioli Annamaria, Luppi Fabrizio, Migaldi Mario, Rossi Giulio
Abstract excerpt
We tested 418 neoplasms along the whole spectrum of primary lung tumor histotypes for epidermal growth factor receptor (EGFR) and K-ras mutations. Clinicopathologic data from 154 patients undergoing treatment with EGFR tyrosine kinase inhibitors (TKIs) were retrospectively studied. A scoring system assigning a score for each positive or negative characteristic (+1, female sex, nonsmoking status, adenocarcinoma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.